C4 Therapeutics, Inc.
CCCC Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$3.21
KIRA · Stoqly’s AI analyst, in plain words
- C4 Therapeutics, Inc. had $35.9M of revenue in fiscal 2025, up 1.0% on the year before.
- Its operating margin was −320.5%, up 15.6 pts: of every 100 in sales, about −321 is left after running the business.
- C4 Therapeutics, Inc. lost $105M in fiscal 2025.
- Free cash flow was −$99.3M in fiscal 2025, −276.2% of revenue.
- C4 Therapeutics, Inc. returned $0.2M to shareholders in fiscal 2025. The diluted share count rose 19.5%.
Market cap
$420M
P/E
—
Revenue
$35.9M
Net income
−$105M
Free cash flow
−$99.3M
Operating margin
−320.5%
C4 Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+1.0%
Only a little. Sales grew 1.0% last year.
Does it make a profit?
−292.1%
No. It lost money last year.
Does profit turn into cash?
−276.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What C4 Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- C4 Therapeutics, Inc.
- CIK
- 0001662579
C4 Therapeutics, Inc. · CCCC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $45.8M | $31.1M | $20.8M | $35.6M | $35.9M |
| Revenue growth | — | −32.1% | −33.3% | 71.4% | 1.0% |
| Operating margin | −179.4% | −416.6% | −669.8% | −336.1% | −320.5% |
| Net income | −$83.9M | −$128M | −$132M | −$105M | −$105M |
| Net margin | −183.2% | −412.2% | −638.3% | −296.0% | −292.1% |
| Diluted EPS | −$1.82 | −$2.62 | −$2.67 | −$1.52 | −$1.27 |
| Cash | |||||
| Cash from operations | −$87.0M | −$106M | −$107M | −$65.2M | −$98.7M |
| Capital expenditure | $1.3M | $5.5M | $1.7M | $0.2M | $0.6M |
| Free cash flow | −$88.2M | −$111M | −$109M | −$65.3M | −$99.3M |
| FCF margin | −192.7% | −358.4% | −523.0% | −183.6% | −276.2% |
| Share buybacks | — | $0.0M | $0.1M | $0.2M | $0.2M |
| Share count change | 304.9% | 6.1% | 1.6% | 39.8% | 19.5% |
| Debt and strength | |||||
| Cash and short-term investments | $309M | $29.8M | $127M | $55.5M | $74.6M |
| Debt incl. finance leases | $10.8M | $11.5M | $0.0M | — | — |
| Shareholders' equity | $390M | $289M | $246M | $216M | $257M |
| Current ratio | 6.4x | 6.5x | 6.3x | 5.7x | 7.8x |
| Returns and quality | |||||
| Return on capital | −71.2% | −37.8% | −91.9% | — | — |
| Return on equity | −25.0% | −37.8% | −49.5% | −45.6% | −44.4% |
| Return on tangible equity | −21.5% | −44.3% | −53.8% | −48.8% | −40.9% |
| Piotroski F-score | 2 | 2 | 2 | 3 | 3 |
| Altman Z'' | 4.2 | 0.8 | −1.1 | −2.5 | −2.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
C4 Therapeutics, Inc. · CCCC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.21 a share, the company is worth $420M.
Source: SEC EDGAR XBRL filings (CIK 0001662579). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.